Viking Therapeutics Inc Market Cap ($3.47 Billion)
Market Cap & Net Worth: Viking Therapeutics Inc (VKTX)
Viking Therapeutics Inc market cap. Viking Therapeutics Inc (NASDAQ:VKTX) has a market capitalization of $3.47 Billion ($3.47 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4350 globally and #1529 in its home market, demonstrating a 5.61% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Viking Therapeutics Inc's stock price $27.28 by its total outstanding shares 127165251 (127.17 Million). Also see Viking Therapeutics Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Viking Therapeutics Inc Market Cap History (2015–2026)
Viking Therapeutics Inc market cap history from 2015 to 2026. Data shows growth from $433.63 Million to $3.47 Billion (14.35% CAGR). Check Viking Therapeutics Inc share price for real-time trading data and today's change.
Index Memberships
Viking Therapeutics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.13% | #117 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #508 of 3165 |
Weight: Viking Therapeutics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Viking Therapeutics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Viking Therapeutics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Viking Therapeutics Inc annual equity growth to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
54664.06x
Viking Therapeutics Inc's market cap is 54664.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $715.94 Million | $10.73K | -$39.49 Million | 66717.02x | N/A |
| 2021 | $584.96 Million | $10.70K | -$54.99 Million | 54664.06x | N/A |
Competitor Companies of VKTX by Market Capitalization
Companies near Viking Therapeutics Inc in the global market cap rankings as of November 1, 2026. Also see Viking Therapeutics Inc total assets for a full breakdown of the balance sheet.
Key companies related to Viking Therapeutics Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Viking Therapeutics Inc (2015–2026)
Market capitalization of Viking Therapeutics Inc from 2015 to today. Between 2015 and today, Viking Therapeutics Inc's market cap moved from $433.63 Million to $ 3.47 Billion, with a yearly change of 14.35%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $3.47 Billion | -22.46% |
| 2025 | $4.47 Billion | -12.57% |
| 2024 | $5.12 Billion | +116.23% |
| 2023 | $2.37 Billion | +97.98% |
| 2022 | $1.20 Billion | +104.35% |
| 2021 | $584.96 Million | -18.29% |
| 2020 | $715.94 Million | -29.80% |
| 2019 | $1.02 Billion | +4.84% |
| 2018 | $972.81 Million | +88.42% |
| 2017 | $516.29 Million | +241.18% |
| 2016 | $151.33 Million | -65.10% |
| 2015 | $433.63 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Viking Therapeutics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $3.47 Billion USD |
| MoneyControl | $3.47 Billion USD |
| MarketWatch | $3.47 Billion USD |
| marketcap.company | $3.47 Billion USD |
| Reuters | $3.47 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Viking Therapeutics Inc
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steato… Read more